Magali Olivier

Summary

Affiliation: International Agency for Research on Cancer
Country: France

Publications

  1. doi request reprint Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes
    Magali Olivier
    International Agency for Research on Cancer, Group of Molecular Carcinogenesis, Lyon, France
    Curr Opin Oncol 23:88-92. 2011
  2. doi request reprint Somatic mutation databases as tools for molecular epidemiology and molecular pathology of cancer: proposed guidelines for improving data collection, distribution, and integration
    M Olivier
    Group of Molecular Carcinogenesis and Biomarkers, International Agency for Research on Cancer, World Health Organization, Lyon, France
    Hum Mutat 30:275-82. 2009
  3. doi request reprint Recent advances in p53 research: an interdisciplinary perspective
    M Olivier
    1Group of Molecular Carcinogenesis and Biomarkers, International Agency for Research on Cancer, World Health Organization, Lyon, France
    Cancer Gene Ther 16:1-12. 2009
  4. ncbi request reprint Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
    Audrey Petitjean
    Group of Molecular Carcinogenesis and Biomarkers, International Agency for Research on Cancer IARC, World Health Organization, Lyon, France
    Hum Mutat 28:622-9. 2007
  5. doi request reprint p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines
    Suresh Anaganti
    International Agency for Research on Cancer, Lyon, France
    Cancer Lett 300:215-24. 2011
  6. doi request reprint p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines
    Lynnette Fernández-Cuesta
    International Agency for Research on Cancer, Lyon, France
    Int J Cancer 128:1813-21. 2011
  7. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
  8. pmc TP53 mutations in human cancers: origins, consequences, and clinical use
    Magali Olivier
    Group of Molecular Carcinogenesis, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Cold Spring Harb Perspect Biol 2:a001008. 2010
  9. doi request reprint Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome
    Edenir I Palmero
    International Agency for Research on Cancer, Group of Molecular Carcinogenesis, Lyon, France
    Curr Opin Oncol 22:64-9. 2010
  10. doi request reprint TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
    Liacine Bouaoun
    Group of Biostatistics, International Agency for Research on Cancer, Lyon Cedex 08, 69372, France
    Hum Mutat 37:865-76. 2016

Collaborators

Detail Information

Publications25

  1. doi request reprint Somatic mutations in cancer prognosis and prediction: lessons from TP53 and EGFR genes
    Magali Olivier
    International Agency for Research on Cancer, Group of Molecular Carcinogenesis, Lyon, France
    Curr Opin Oncol 23:88-92. 2011
    ..We used two examples of genes, TP53 and EGFR, which are somatically altered by intragenic mutations in common cancer types to illustrate how somatic mutations have followed very different routes to clinical applications...
  2. doi request reprint Somatic mutation databases as tools for molecular epidemiology and molecular pathology of cancer: proposed guidelines for improving data collection, distribution, and integration
    M Olivier
    Group of Molecular Carcinogenesis and Biomarkers, International Agency for Research on Cancer, World Health Organization, Lyon, France
    Hum Mutat 30:275-82. 2009
    ..This initiative is meant to promote collaboration and discussion on these issues and the development of adequate resources that would avoid the loss of extremely valuable information generated by years of basic and clinical research...
  3. doi request reprint Recent advances in p53 research: an interdisciplinary perspective
    M Olivier
    1Group of Molecular Carcinogenesis and Biomarkers, International Agency for Research on Cancer, World Health Organization, Lyon, France
    Cancer Gene Ther 16:1-12. 2009
    ..New opportunities for translational research for improving cancer detection, prognosis, prevention and therapy based upon the integration of this knowledge are described...
  4. ncbi request reprint Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database
    Audrey Petitjean
    Group of Molecular Carcinogenesis and Biomarkers, International Agency for Research on Cancer IARC, World Health Organization, Lyon, France
    Hum Mutat 28:622-9. 2007
    ..These results provide new insights into the factors that shape mutation patterns and influence mutation phenotype, which may have clinical interest...
  5. doi request reprint p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines
    Suresh Anaganti
    International Agency for Research on Cancer, Lyon, France
    Cancer Lett 300:215-24. 2011
    ....
  6. doi request reprint p53 status influences response to tamoxifen but not to fulvestrant in breast cancer cell lines
    Lynnette Fernández-Cuesta
    International Agency for Research on Cancer, Lyon, France
    Int J Cancer 128:1813-21. 2011
    ..These results bring new insights into the prognostic role of p53 in breast cancer and into possible mechanisms underlying tamoxifen resistance...
  7. pmc Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 8, France
    Breast Cancer Res 14:R70. 2012
    ....
  8. pmc TP53 mutations in human cancers: origins, consequences, and clinical use
    Magali Olivier
    Group of Molecular Carcinogenesis, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Cold Spring Harb Perspect Biol 2:a001008. 2010
    ..Here, we summarize current knowledge on TP53 gene variations observed in human cancers and populations, and current clinical applications derived from this knowledge...
  9. doi request reprint Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome
    Edenir I Palmero
    International Agency for Research on Cancer, Group of Molecular Carcinogenesis, Lyon, France
    Curr Opin Oncol 22:64-9. 2010
    ....
  10. doi request reprint TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data
    Liacine Bouaoun
    Group of Biostatistics, International Agency for Research on Cancer, Lyon Cedex 08, 69372, France
    Hum Mutat 37:865-76. 2016
    ..We thus provide an update of current knowledge on TP53 variations in human cancer as well as inform users on the efficient use of the IARC TP53 Database. ..
  11. doi request reprint Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect
    Sonia Garritano
    International Agency for Research on Cancer IARC, Lyon, Rhone, France
    Hum Mutat 31:143-50. 2010
    ..This historical circumstance and the relatively low penetrance before the age of 30 may have contributed to the maintenance of this pathogenic mutation in a large, open population...
  12. pmc Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods
    Ewy Mathe
    International Agency for Research on Cancer, Lyon, France
    Nucleic Acids Res 34:1317-25. 2006
    ..9% specificity and sensitivity, respectively). These results further demonstrate the utility of the Align-GVGD method, which was previously applied to BRCA1. Align-GVGD is available online at http://agvgd.iarc.fr...
  13. ncbi request reprint Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
    Magali Olivier
    IARC, Lyon, Cedex 8, France
    Cancer Res 63:6643-50. 2003
    ..004). These observations have clinical implications for genetic testing and tumor surveillance in LFS/LFL families...
  14. pmc TP53 mutation p.R337H in gastric cancer tissues of a 12-year-old male child: evidence for chimerism involving a common mutant founder haplotype: case report
    Edaise M da Silva
    International Agency for Research on Cancer, Lyon, France
    BMC Cancer 11:449. 2011
    ..We report a case of invasive well-differentiated metastatic gastric cancer in a Brazilian 12-year-old boy without documented familial history of cancer...
  15. pmc MutSpec: a Galaxy toolbox for streamlined analyses of somatic mutation spectra in human and mouse cancer genomes
    Maude Ardin
    Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, F69372, Lyon, France
    BMC Bioinformatics 17:170. 2016
    ..To make such analyses accessible to a wider community of researchers with no programming expertise, we have developed within the web-based user-friendly platform Galaxy a first-of-its-kind package called MutSpec...
  16. doi request reprint Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort
    Chiara Scoccianti
    International Prevention Research Institute, Lyon, France
    Eur Respir J 40:177-84. 2012
    ..These results suggest that mutations are good markers of different aetiologies and histopathological forms of lung cancers but have little prognostic value, with the exception of KRAS mutation, which may have a prognostic value in ADC...
  17. ncbi request reprint The tumor suppressor gene TP53: implications for cancer management and therapy
    Severine Seemann
    International Agency for Research on Cancer, Lyon, France
    Crit Rev Clin Lab Sci 41:551-83. 2004
    ..In addition, detection of mutant TP53 may also serve as a marker for early cancer detection, prediction, and prognosis. In this review, we discuss the mechanisms underlying these approaches and their perspectives for cancer therapy...
  18. doi request reprint Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
    Claire Tissot
    Department of Acute Respiratory Medicine and Thoracic Oncology Department, Lyon Sud Hospital and Lyon University Cancer Institute, Lyon University Hospital, Pierre Benite, France International Agency for Research on Cancer, Molecular Mechanisms and Biomarkers Group, Lyon, France
    Eur Respir J 46:1773-80. 2015
    ..cfDNA may be a biomarker for the assessment of prognosis in NSCLC. However, total concentration of cfDNA does not appear to predict chemotherapy response. ..
  19. doi request reprint Estrogen levels act as a rheostat on p53 levels and modulate p53-dependent responses in breast cancer cell lines
    Lynnette Fernández-Cuesta
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, Lyon, France
    Breast Cancer Res Treat 125:35-42. 2011
    ..It would thus be important to further characterize the influence of ERα pathway on the predictive value of TP53 mutation status in specifically designed clinical trials, as it may open perspectives for improving breast cancer treatment...
  20. pmc Low-Coverage Exome Sequencing Screen in Formalin-Fixed Paraffin-Embedded Tumors Reveals Evidence of Exposure to Carcinogenic Aristolochic Acid
    Xavier Castells
    Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, Lyon, France
    Cancer Epidemiol Biomarkers Prev 24:1873-81. 2015
    ....
  21. doi request reprint Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002
    Sébastien Couraud
    International Agency for Research on Cancer, Section of Mechanisms of Carcinogenesis, Molecular Mechanisms and Biomarkers Group, Lyon Cedex, France Department of Pulmonology, Lyon Sud University Hospital, Hospices Civils de Lyon, Lyon, France Lyon Sud Faculty of Medicine, Lyon 1 University, Pierre Benite Cedex, France
    Clin Cancer Res 20:4613-24. 2014
    ..Here, we evaluated next-generation sequencing (NGS) on cfDNA samples obtained from a consecutive series of patients for the screening of a range of clinically relevant mutations...
  22. ncbi request reprint The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer
    Magali Olivier
    IARC, Lyon, France
    Clin Cancer Res 12:1157-67. 2006
    ..These results, obtained on the largest series analyzed thus far, show that TP53 mutations identified by gene sequencing have an independent prognostic value in breast cancer and could have potential uses in clinical practice...
  23. ncbi request reprint The IARC TP53 database: new online mutation analysis and recommendations to users
    Magali Olivier
    Molecular Carcinogenesis Group, International Agency for Research on Cancer, World Health Organization, Lyon, France
    Hum Mutat 19:607-14. 2002
    ..In addition, a new on-line application to retrieve somatic mutation data and analyze mutation patterns is now available. We also discuss limitations on the use of the database and provide recommendations to users...
  24. ncbi request reprint Upper urinary tract urothelial cancers: where it is A:T
    Magali Olivier
    International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon, France
    Nat Rev Cancer 12:503-4. 2012
    ..Despite a ban on the use of plants of the Aristolochia genus in herbal medicine, as they contain known carcinogens, urothelial carcinoma attributable to the use of this plant seems to be more common than previously thought...
  25. ncbi request reprint TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes
    A Petitjean
    International Agency for Research on Cancer, Lyon, France
    Oncogene 26:2157-65. 2007
    ..Further studies are needed to determine how TP53 haplotypes or loss of alleles interact with mutations to modulate their impact on cancer development and prognosis...